Skip to content


Evrysdi (risdiplam) is a small molecule pharmaceutical. Risdiplam was first approved as Evrysdi on 2020-08-07. It has been approved in Europe to treat spinal muscular atrophy. Evrysdi's patents are valid until 2035-05-11 (FDA).
Trade Name Evrysdi
Common Name Risdiplam
Indication spinal muscular atrophy
Drug Class Survival motor neurin SMN1 and SMN2 splicing modulators
Get full access now